Epigenomics, RNA and Gene Regulation

表观基因组学、RNA 和基因调控

• 批准号: 10394825
• 负责人: MICHAEL F CAREY
• 金额: $ 15.53万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10394825
• 关键词: Achievement; Address; Animal Model; Animals; Bioinformatics; Biological Models; Biological Process; Biology; Breast; Cancer Biology; Cancer Burden; Cancer Center Support Grant; Catchment Area; Cell Cycle; Cell Differentiation process; Cell model; Cells; Chromatin; Clinical; Collaborations; Colorectal; Computer Analysis; County; Coupled; DNA Sequence Alteration; DNA sequencing; Data; Dependence; Development; Diagnostic; Direct Costs; Disease; Doctor of Philosophy; Ensure; Environment; Faculty; Fostering; Funding; Gene Expression Regulation; Genes; Genetic Transcription; Genome; Genomics; Goals; High-Throughput Nucleotide Sequencing; Histone Deacetylase Inhibitor; Human Resources; Immune response; Inflammation; Informatics; Institution; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Knowledge; Link; Liver; Los Angeles; Lung; Malignant Neoplasms; Metabolic; Methodology; Modeling; Molecular; Organism; Paper; Pathologic Processes; Peer Review; Physiological Processes; Plants; Postdoctoral Fellow; Program Development; Prostate; Proteomics; Publications; RNA; Regulation; Regulator Genes; Research; Research Personnel; Schools; Science; Structure; Students; Technology; Therapeutic; Training; Training Programs; Translating; Translations; Viral; Viral Oncogene; Yeasts; cancer cell; cancer genome; cancer initiation; cancer type; cell free DNA; epigenome; epigenomics; expectation; genome-wide; innovation; insight; interest; large datasets; lipid metabolism; member; metaplastic cell transformation; new technology; next generation; novel; novel diagnostics; novel strategies; pre-clinical; preclinical study; prognostic; programs; recruit; stem cell self renewal; tool; translational applications; translational physician; translational scientist; treatment strategy; tumor; tumor progression; tumorigenesis

EPIGENOMICS, RNA, AND GENE REGULATION RESEARCH PROGRAM (ERGR) ABSTRACT The Epigenomics, RNA, and Gene Regulation Research Program (ERGR), led by Michael Carey, PhD (Program Director) and Siavash Kurdistani, MD (Program Co-Director), is the most basic of the JCCC Research Programs. Program objectives are to support exceptional JCCC researchers and teams, to ensure ongoing Program robustness with strategic recruitments and training, and to innovate breakthroughs in gene regulation, RNA biology, and bioinformatics with impact in cancer. The expectation is that ERGR investigator discoveries will uncover vulnerabilities for targeting by novel diagnostic and anti-tumor treatment strategies. ERGR investigators employ a range of model systems, from yeast and plants to cancer cells and small animals, to elucidate mechanisms of gene regulation, from chromatin and transcription to RNA biology, to understand and dissect alterations in cancer. Program studies extend to physiological and pathological processes implicated in cancer including cell differentiation, inflammation, and lipid metabolism. ERGR leads in developing new technologies and methodologies, such as advanced informatics for high-throughput experimental tools, and provides expertise to researchers in all six JCCC Research Programs. Although focused on epigenomics and gene regulatory mechanisms, ERGR strives to translate new knowledge to preclinical and clinical settings, with Program discoveries underpinning clinical HDAC inhibitor development and cell free DNA diagnostics. The ERGR Research Program has 33 members drawn from five UCLA schools and partner institution, Caltech, representing 13 departments. As of March 1, 2019, Program support was $11,256,579 in direct cost funding, of which $9,904,290 (88%) is peer-reviewed, and $1,031,199 (9%) is NCI funding. Program discoveries resulted in 506 publications during the prior project period, of which 10% were intra-programmatic collaborations, and 19% were inter-programmatic collaborations. In addition, 271 (54%) Program publications were with external collaborators and 337 (67%) of publications were in high-impact (IF ≥10, or field leading) journals. As an example, one achievement in the prior period was enormous strengthening of bioinformatics via recruitment. Scientifically, studies revealed how a viral oncogene exploits cell machinery to induce cell cycling and simultaneously block an anti-viral immune response. Additionally, new insights into the metabolic dependencies of stem cell self- renewal and differentiation informed how such dependencies may provide a permissive environment for tumorigenesis in the presence of pre-disposing genetic mutations. ERGR investigators cultivate a collegial environment with many structured opportunities to exchange ideas, research findings, and scientific discussions amongst Program faculty, postdocs, and students. These interactions help establish valuable collaborations that raise the quality of Program science and inspire interest in cancer-related problems. An ERGR Program guiding principle is to foster the discovery of fundamental biological processes whose alterations may contribute to cancer development and progression, which supports the ultimate JCCC goal of defeating this dreaded disease.

表观基因组学、RNA 和基因调控研究计划 (ERGR) 抽象的 表观基因组学、RNA 和基因调控研究计划 (ERGR)，由 Michael Carey 博士领导 （项目总监）和 Siavash Kurdistani 医学博士（项目联合总监）是 JCCC 研究的最基本 节目。计划目标是支持杰出的 JCCC 研究人员和团队，以确保持续 通过战略招募和培训来增强计划的稳健性，并在基因调控方面实现创新突破， RNA 生物学和生物信息学对癌症的影响。预计 ERGR 研究人员会发现 将发现新的诊断和抗肿瘤治疗策略的靶向弱点。 ERGR 研究人员采用了一系列模型系统，从酵母和植物到癌细胞和小动物， 阐明从染色质和转录到 RNA 生物学的基因调控机制，以了解和 剖析癌症的变化。计划研究扩展到涉及的生理和病理过程 癌症，包括细胞分化、炎症和脂质代谢。 ERGR 在开发新产品方面处于领先地位 技术和方法，例如用于高通量实验工具的高级信息学，以及 为所有六个 JCCC 研究项目的研究人员提供专业知识。尽管专注于表观基因组学和 基因调控机制，ERGR 致力于将新知识转化为临床前和临床环境， 支持临床 HDAC 抑制剂开发和无细胞 DNA 诊断的项目发现。 ERGR 研究计划有 33 名成员，来自加州大学洛杉矶分校的五所学校和合作机构加州理工学院、 代表13个部门。截至 2019 年 3 月 1 日，计划支持的直接成本资金为 11,256,579 美元，其中 其中 9,904,290 美元（88%）是经过同行评审的，1,031,199 美元（9%）是 NCI 资助的。程序发现导致 上一个项目期间发表了 506 篇出版物，其中 10% 是项目内合作，19% 是项目内合作 是跨项目合作。此外，271 份 (54%) 计划出版物是与外部合作的 合作者和 337 篇 (67%) 的出版物发表在高影响力（IF ≥10，或领域领先）期刊上。举个例子， 上一时期的一项成就是通过招聘极大地加强了生物信息学。从科学角度来说， 研究揭示了病毒癌基因如何利用细胞机制诱导细胞周期并同时阻断 抗病毒免疫反应。此外，对干细胞自我代谢依赖性的新见解 更新和分化告诉我们这种依赖关系如何为 存在易感基因突变的情况下发生肿瘤。 ERGR 调查员培养了一个合议 提供许多交流想法、研究成果和科学讨论的结构化机会的环境 项目教师、博士后和学生。这些互动有助于建立有价值的合作 提高计划科学的质量并激发对癌症相关问题的兴趣。 ERGR 计划指导 原则是促进基本生物过程的发现，这些过程的改变可能有助于 癌症的发展和进展，这支持 JCCC 战胜这种可怕疾病的最终目标。